2444. Administration of ferrous sulfate drops has significant effects on the gut microbiota of iron-sufficient infants: a randomised controlled study.
作者: Kotryna Simonyté Sjödin.;Magnus Domellöf.;Carina Lagerqvist.;Olle Hernell.;Bo Lönnerdal.;Ewa A Szymlek-Gay.;Andreas Sjödin.;Christina E West.;Torbjörn Lind.
来源: Gut. 2019年68卷11期2095-2097页 2445. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
作者: Jeroni Luna.;Jacopo Boni.;Miriam Cuatrecasas.;Xavier Bofill-De Ros.;Estela Núñez-Manchón.;Meritxell Gironella.;Eva C Vaquero.;Maria L Arbones.;Susana de la Luna.;Cristina Fillat.
来源: Gut. 2019年68卷8期1465-1476页
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis.
2447. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
作者: Alexandra D Frolkis.;Isabelle A Vallerand.;Abdel-Aziz Shaheen.;Mark W Lowerison.;Mark G Swain.;Cheryl Barnabe.;Scott B Patten.;Gilaad G Kaplan.
来源: Gut. 2019年68卷9期1606-1612页
Depression is associated with IBD, but the effect of antidepressants on IBD has been sparsely studied. We assessed the impact of depression and antidepressant therapies on the development of IBD.
2448. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
作者: Marina Koutsioumpa.;Maria Hatziapostolou.;Christos Polytarchou.;Ezequiel J Tolosa.;Luciana L Almada.;Swapna Mahurkar-Joshi.;Jennifer Williams.;Ana Belen Tirado-Rodriguez.;Sara Huerta-Yepez.;Dimitrios Karavias.;Helen Kourea.;George A Poultsides.;Kevin Struhl.;David W Dawson.;Timothy R Donahue.;Martín E Fernández-Zapico.;Dimitrios Iliopoulos.
来源: Gut. 2019年68卷7期1271-1286页
Despite advances in the identification of epigenetic alterations in pancreatic cancer, their biological roles in the pathobiology of this dismal neoplasm remain elusive. Here, we aimed to characterise the functional significance of histone lysine methyltransferases (KMTs) and demethylases (KDMs) in pancreatic tumourigenesis.
2449. SWI/SNF component ARID1A restrains pancreatic neoplasia formation.
作者: Sam C Wang.;Ibrahim Nassour.;Shu Xiao.;Shuyuan Zhang.;Xin Luo.;Jeon Lee.;Lin Li.;Xuxu Sun.;Liem H Nguyen.;Jen-Chieh Chuang.;Lan Peng.;Scott Daigle.;Jeanne Shen.;Hao Zhu.
来源: Gut. 2019年68卷7期1259-1270页
ARID1A is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of ARID1A mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies.
2454. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver.
作者: Aida Habib.;Dina Chokr.;JingHong Wan.;Pushpa Hegde.;Morgane Mabire.;Matthieu Siebert.;Lara Ribeiro-Parenti.;Maude Le Gall.;Philippe Lettéron.;Nathalie Pilard.;Abdellah Mansouri.;Arthur Brouillet.;Matteo Tardelli.;Emmanuel Weiss.;Pauline Le Faouder.;Hervé Guillou.;Benjamin F Cravatt.;Richard Moreau.;Michael Trauner.;Sophie Lotersztajn.
来源: Gut. 2019年68卷3期522-532页
Sustained inflammation originating from macrophages is a driving force of fibrosis progression and resolution. Monoacylglycerol lipase (MAGL) is the rate-limiting enzyme in the degradation of monoacylglycerols. It is a proinflammatory enzyme that metabolises 2-arachidonoylglycerol, an endocannabinoid receptor ligand, into arachidonic acid. Here, we investigated the impact of MAGL on inflammation and fibrosis during chronic liver injury.
2455. Tight junction proteins in gastrointestinal and liver disease.
Over the past two decades a growing body of evidence has demonstrated an important role of tight junction (TJ) proteins in the physiology and disease biology of GI and liver disease. On one side, TJ proteins exert their functional role as integral proteins of TJs in forming barriers in the gut and the liver. Furthermore, TJ proteins can also be expressed outside TJs where they play important functional roles in signalling, trafficking and regulation of gene expression. A hallmark of TJ proteins in disease biology is their functional role in epithelial-to-mesenchymal transition. A causative role of TJ proteins has been established in the pathogenesis of colorectal cancer and gastric cancer. Among the best characterised roles of TJ proteins in liver disease biology is their function as cell entry receptors for HCV-one of the most common causes of hepatocellular carcinoma. At the same time TJ proteins are emerging as targets for novel therapeutic approaches for GI and liver disease. Here we review our current knowledge of the role of TJ proteins in the pathogenesis of GI and liver disease biology and discuss their potential as therapeutic targets.
2456. The regenerating family member 3 β instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure.
作者: Nadine Waldschmitt.;Sho Kitamoto.;Thomas Secher.;Vassiliki Zacharioudaki.;Olivier Boulard.;Emilie Floquet.;Myriam Delacre.;Bruno Lamas.;Hang-Phuong Pham.;Adrien Six.;Mathias L Richard.;Jean-Charles Dagorn.;Gérard Eberl.;Philippe Langella.;Jean-Marc Chatel.;Bernhard Ryffel.;Juan Lucio Iovanna.;Lionel F Poulin.;Harry Sokol.;Nobuhiko Kamada.;Mathias Chamaillard.
来源: Gut. 2019年68卷7期1190-1199页
Loss of the Crohn's disease predisposing NOD2 gene results in an intestinal microenvironment conducive for colonisation by attaching-and-effacing enteropathogens. However, it remains elusive whether it relies on the intracellular recruitment of the serine-threonine kinase RIPK2 by NOD2, a step that is required for its activation of the transcription factor NF-κB.
2457. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
作者: De-Shen Wang.;Ze-Xian Liu.;Yun-Xin Lu.;Hua Bao.;Xue Wu.;Zhao-Lei Zeng.;Zekun Liu.;Qi Zhao.;Cai-Yun He.;Jia-Huan Lu.;Zhi-Qiang Wang.;Miao-Zhen Qiu.;Feng Wang.;Feng-Hua Wang.;Yu-Hong Li.;Xiao-Nan Wang.;Dan Xie.;Wei-Hua Jia.;Yang W Shao.;Rui-Hua Xu.
来源: Gut. 2019年68卷7期1152-1161页
To monitor trastuzumab resistance and determine the underlying mechanisms for the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric cancer (mGC).
2458. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial.
作者: Giles Major.;Lucy Bradshaw.;Nafisa Boota.;Kirsty Sprange.;Mathew Diggle.;Alan Montgomery.;Aida Jawhari.;Robin C Spiller.; .
来源: Gut. 2019年68卷7期1224-1231页
Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using 'follow-on' rifaximin treatment. We aimed to assess the efficacy of rifaximin treatment in preventing recurrence.
|